ΔSLE-DAS≥1.72 | ΔSLEDAI-2K≥4 | |||||||
Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | |
Derivation cohort | ||||||||
Clinically meaningful improvement | 82.1 | 96.9 | 87.3 | 95.4 | 44.8 | 96.5 | 76.9 | 87.0 |
Clinically meaningful worsening | 93.1 | 97.7 | 90.0 | 98.5 | 46.6 | 99.6 | 96.4 | 89.5 |
Validation cohort | ||||||||
Clinically meaningful improvement | 89.5 | 100 | 100 | 98.9 | 47.4 | 99.4 | 90 | 94.5 |
Clinically meaningful worsening | 95.5 | 98.2 | 87.5 | 99.4 | 59.1 | 99.4 | 92.9 | 94.9 |
SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SLE-DAS, SLE Disease Activity Score.
NPV, negative predictive value (%); PPV: positive predictive value (%); SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; SLE-DAS, SLE Disease Activity Score; Sens, sensitivity (%); Spec, specificity (%).